CONCLUSIONS -The cohort of patients enrolled in PROactive is a typical type 2 diabetic population at high risk of further macrovascular events. The characteristics of this population are ideal for assessing the ability of pioglitazone to reduce the cardiovascular risk of patients with type 2 diabetes.
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I t is estimated that 115 million people worldwide suffered from diabetes in 1995 and that this figure will increase to 215 million by 2010 (1) and 300 million by 2025 (2). The social and economic consequences of the management of diabetes and its complications make it a major public health issue. Patients with diabetes have an increased risk of microand macrovascular disease, with an overall 25% reduction in life expectancy compared with the general population. This is mainly due to cardiovascular deaths; the risk of coronary heart disease is increased two-to fourfold in this population (3,4). Furthermore, the risk of cardiovascular complications in patients with diabetes is equivalent to that of people without diabetes who have suffered previous acute myocardial infarction (MI) (5).
Recent studies have shown that intensive glycemic control significantly improves microvascular complications in type 1 and type 2 diabetes, although to date glucose-lowering intervention studies have failed to demonstrate a marked effect on the incidence of cardiovascular events (6 -9). However, in the U.K. Prospective Diabetes Study (UKPDS), the reduction in the risk of cardiovascular disease and decrease in total mortality, although less prominent than the improvements in microvascular disease, reached significance in a subgroup of overweight patients receiving metformin (6,10). The UKPDS also demonstrated the importance of reducing HbA 1c , which is a risk factor for vascular disease in patients with diabetes (6). Other risk factors that predispose to cardiovascular complications include: smoking, dyslipidemia (low HDL cholesterol and elevated plasma triglycerides), hypertension, and central obesity, all of which may be linked by insulin resistance (6, 11, 12) .
Pioglitazone is a thiazolidinedione (TZD) approved for the treatment of type 2 diabetes. As a nuclear peroxisome proliferator-activated receptor-␥ agonist, pioglitazone affects insulin resistance by increasing insulin sensitivity in the liver, muscle, and adipose tissue (13,14). Pioglitazone has proven glucose-lowering efficacy, as reflected by improvements in plasma glucose levels and HbA 1c (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . Insulin resistance is a major determinant of hyperglycemia. To overcome insulin resistance, the ␤-cell is forced to produce more insulin, with the consequent functional stress (29) . Treatments that provide effective decreases in the workload of the ␤-cell and stabilize its function may improve its longevity (30) . Accumulating evidence (for example, evaluations by homeostasis model assessment) also suggests that ␤-cell function may be preserved (30 -34) with TZDs, thus the antihyperglycemic efficacy of pioglitazone or any other concomitant oral glucose-lowering agent could be prolonged.
Insulin resistance, together with hyperinsulinemia, plays a part in the pathogenesis of the metabolic syndrome, and hyperinsulinemia is an independent risk factor for cardiovascular disease (35, 36) . Agents that address the underlying pathology in the liver, muscle, and fat can also have an impact on markers of the metabolic syndrome. A number of studies suggest that pioglitazone confers clinical benefits beyond a glucose-lowering effect, such as improvements in dyslipidemia and atherosclerosis (22) (23) (24) (25) (26) (27) (28) 37, 38) .
Type 2 diabetes is associated with dyslipidemia characterized by increased triglycerides and low levels of HDL cholesterol (39) . Pioglitazone has been shown to improve specific lipid abnormalities commonly associated with insulin resistance. Treatment with pioglitazone significantly elevates HDL cholesterol levels, decreases triglyceride levels, and changes the size of LDL particles from small and dense to large and buoyant (less atherogenic) particles that are less susceptible to oxidation (22) (23) (24) (25) (26) (27) . Microalbuminuria is an independent risk factor for cardiovascular disease (40) . Treatment with TZDs decreases microalbuminuria in patients with type 2 diabetes and as such may have a role in treating diabetic nephropathy (41) (42) (43) .
Inflammation within the vascular wall is at the core of atherosclerosis and gives an indication of vascular risk. Studies (37,38,44 -50) suggest that the development or progression of atherosclerotic disease in patients with type 2 diabetes may be modulated using TZDs by their ability to inhibit vascular smooth muscle cell proliferation and migration and to decrease vascular inflammation (as measured by C-reactive protein), carotid intima-media thickness (as measured by B-mode ultrasonography), and plasminogen activator inhibitor-1 levels, reflecting improved hemostatic function. Taken together, these findings suggest that pioglitazone has the potential to slow the progression of cardiovascular disease in addition to lowering glucose.
The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) is one of a series of studies evaluating the effects of pioglitazone on the progression of atherosclerosis and testing the hypothesis that pioglitazone lowers the incidence of macrovascular complications in high-risk patients with type 2 diabetes. In this double-blind, placebo-controlled study, pioglitazone is used as "add-on" therapy to current treatment, which is to be continuously optimized throughout the trial to allow patients to receive the best possible therapy available. Further studies to compare the effects of pioglitazone on the progression of atherosclerosis include a study evaluating Carotid intimamedia tHICkness in Atherosclerosis using pioGlitazOne (the CHICAGO study) and the Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE) study. The design and baseline data of PROactive are presented in this article.
RESEARCH DESIGN AND METHODS -Male or female patients with type 2 diabetes, aged 35-75 years, were included in the study if they had an HbA 1c level above the upper limit of normal (i.e., local equivalent of 6.5% for a Diabetes Control and Complications Trial-traceable assay), despite management of diabetes with diet alone or with oral blood glucose-lowering agents. Patients currently using pioglitazone or any other TZD were excluded. Insulin was allowed only if previously given in combination with oral blood glucose-lowering agents. Patients are at increased risk of macrovascular disease as determined by the presence of one or more of the following criteria: MI or stroke at least 6 months before entry into the study, percutaneous coronary intervention or coronary artery bypass graft at least 6 months before study entry, acute coronary syndrome (defined as treatment in a hospital as a consequence of one or more episodes of ischemic discomfort at rest and characterized by electrocardiogram changes and/or elevation of a cardiac serum marker to an extent not indicative of MI) at least 3 months before study entry, objective evidence of coronary artery disease (defined as positive exercise test, angiography with at least one stenosis of Ͼ50%, or positive scintigraphy), or history of symptomatic peripheral arterial obstructive disease (as evidenced by current claudication, confirmed by an ankle [or toe] brachial pressure index Ͻ0.90 or an amputation).
The main exclusion criteria were any signs of type 1 diabetes (including any history of ketoacidosis or requirement for insulin therapy within 1 year of diagnosis); insulin as sole therapy for diabetes; planned revascularization; symptomatic heart failure (New York Heart Association class II or above); leg ulcers, gangrene, or pain at rest; hemodialysis; or significantly impaired hepatic function (defined as serum alanine aminotransferase Ͼ2.5 times the upper limit of normal).
PROactive is a randomized, doubleblind, placebo-controlled outcome study. Pioglitazone or placebo is given as add-on therapy to existing diabetes management (including diet and exercise). The investigators are encouraged to maintain glycemia within the limits outlined in the International Diabetes Federation (IDF) Europe Guidelines (Ͻ6.5%) (51), which was highlighted and circulated to all investigators. Study medication is assigned using a central interactive voice-response system. During a forced-titration phase in the first 2 months of treatment, the pioglitazone dose is increased stepwise from 15 to 30 mg and then up to 45 mg, with the objective of maintaining patients on the maximum-tolerated dose. At any time during the study, the dose of pioglitazone can be increased or decreased within the 15-to 45-mg range, based on tolerability. Any other medication required (including non-TZD oral glucose-lowering agents) may be administered concomitantly. Throughout the study the investigators were encouraged to optimize all therapy according to the IDF Europe Guidelines, in particular lipid-lowering and antihypertensive therapy. Patients who discontinue the study medication are followed until the end of the study. It is expected that the study will finish during the course of 2005.
Following randomization, patients attend visits after 1 and 2 months, then every 2 months for the first year and quarterly until the final visit. Vital signs and body weight are measured at each visit. Lipids, HbA 1c , creatinine, and liver tests are analyzed at a central laboratory. Blinded follow-up of all patients continues until both of the following targets are achieved: 1) the last patient recruited has been followed for at least 30 months, and 2) the number of patients with one or more end point events is at least 760.
Efficacy evaluations
A composite cardiovascular disease end point is used because the aim of the study is to evaluate the overall effects on macrovascular disease. The primary end point variable is the time from randomization to the first occurrence of any of the events in the following composite: all-cause mortality; nonfatal MI; acute coronary syndrome; cardiac intervention, including coronary artery bypass graft, or percutaneous coronary intervention; stroke; major leg amputation (above the ankle); bypass surgery; or revascularization in the leg. The end points are adjudicated by an independent panel. Secondary end points include the individual components of the primary end point and cardiovascular mortality.
Other measurements comprise cause of death, time to start of permanent insulin use, transient ischemic attack, treatment with retinal photocoagulation, carotid intervention, number of days of hospitalization for any cause, and use of antihypertensive, lipid-lowering, and blood glucose-lowering medications.
Safety evaluations
The incidence of serious and nonserious adverse events will be reported. Patients who present with ketoacidosis, elevated liver tests (alanine aminotransferase more than three times the upper limit of normal) on two consecutive occasions, or patients who become pregnant will be discontinued from study medication but will be followed until the end of the study.
Statistical considerations
The sample size calculation is based on the event rates in patients with diabetes, as published in major clinical trials. In the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT), ϳ32% of the diabetic population died from coronary heart disease or had a nonfatal MI or confirmed stroke over the 5.1-year follow-up (52), i.e., a rate of 7.3% per year. In a post hoc subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), patients with diabetes were found to have an annual rate of death or major event from coronary heart disease of ϳ6% (53) . Based on the assumption of an annual rate of 6% for macrovascular events in the placebo group and an average follow-up of 3 years, a minimum of 5,000 patients (2,500 per treatment group) are necessary in order to observe a minimum of 760 first events. This provides 91% power to detect a reduction of at least 20% in the primary end point event rate (by log-rank test).
Two interim analyses will be conducted by an Independent Statistical Center when ϳ50 and 75% of the target number of end point events are reached and then reported to the Data and Safety Monitoring Committee. This provides the opportunity to stop the study early if the benefits of pioglitazone are unambiguous. Each interim analysis will consider a onesided log-rank test for the superiority of pioglitazone. All study outcomes will be analyzed on an intention-to-treat basis, defined as a patient having received at least one dose of study medication.
Study organization
An International Steering Committee is responsible for the overall design and conduct of the study. It comprises the National Principal Investigators and the Executive Committee for the daily management of the study. A Data and Safety Monitoring Committee reviews the outcome and safety data at regular intervals during the study, while end points are confirmed by an Endpoint Adjudication Panel and Committee.
The study protocol has been approved by local/national ethics committees and regulatory bodies, as appropriate. The study is carried out in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines.
RESULTS

Baseline characteristics
Demography. By the end of April 2002, a total of 5,238 patients were recruited in 321 centers from 19 European countries; enrollment was then closed. The majority of the patients enrolled in the study are male (66.1%). The mean age at the time of entry is 61.8 years, and the mean time since diagnosis of type 2 diabetes is 9.5 years ( (Table 2) . Other patient history. Based on the actual reading of blood pressure at baseline (Table 3) .
CONCLUSIONS -Macrovascular mortality and morbidity are the biggest risks for patients with diabetes, and type 2 diabetes is associated with a two-to fourfold increased risk of coronary heart disease. Other cardiovascular risk factors, such as dyslipidemia and hypertension, are also often present in patients with type 2 diabetes. Type 2 diabetes itself is now considered as an independent coronary heart disease risk factor (54) .
The Multiple Risk Factor Intervention Trial (MRFIT) provided evidence that tight control of hypertension, cholesterol, and smoking reduced cardiovascular mortality in patients with type 2 diabetes (55) . In the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAP-RIE) study, the benefit of intervention with antiplatelet medication was greater in patients with peripheral vascular disease than in those with coronary or cerebral disease (56). Previous studies examining the impact of the management of dyslipidemia and hypertension have shown beneficial effects on the reduction of cardiovascular events in patients with type 2 diabetes (52, 53, (57) (58) (59) (60) (61) . The UKPDS demonstrated that intensive glycemic control of type 2 diabetes aids in reducing all microvascular complications-for every 1% decrease in HbA 1c there was an associated 37% reduction in microvascular complications (9). However, to date there is no conclusive evidence that intervention with conventional glucose-lowering agents is successful in modifying macrovascular disease.
Pioglitazone is known to improve glycemic control and also to possess additional properties that may have an impact on clinical vascular outcomes. It is conceivable that these characteristics are related to its ability to reduce insulin resistance and the associated disorders. Studies of nonhypoglycemic effects of pioglitazone have shown improvements in several cardiovascular risk factors, including modification of lipids and independent predictors of coronary heart disease (e.g., microalbuminuria and plasminogen activator inhibitor-1) and reductions in carotid intima-media thickness that could result in decreased morbidity for macrovascular disease (22) (23) (24) (25) (26) (27) (28) 37, 38) .
PROactive is designed to investigate whether the addition of pioglitazone to patients' usual medications for glycemic, lipidemic, and hypertensive management will reduce total mortality and macrovascular morbidity in high-risk patients. In addition, it assesses treatment effects on individual risk factors for vascular complications in type 2 diabetes. Optimization of the management of lipids, glycemia, and blood pressure is highly recommended to give patients the best possible available management.
Baseline data presented here show 
